Ultrasound contrast imaging of angiogenisis in a murine tumor model

• Published in: The Journal of the Acoustical Society of America 2008-05, Vol.123 (5_Supplement), p.3112-3112
• Main Authors: Lucidarme, Olivier, Taillade, Laurent, Guibal, Aymeric, Mule, Sebastien, Comperat, Eva, Badachi, Yasmina, Jouannot, Erwan, Rixe, Olivier, Bridal, Lori
• Format: Article
• Language: English
• ISSN: 0001-4966; 1520-8524
• DOI: 10.1121/1.2933004

Microvascularization modifications should precede tumor size-changes during anti-angiogenic therapy. We applied contrast functional ultrasound imaging (fUSI) to detect changes in Wilms tumors with anti-angiogenic treatment (Bevacizumab). Human Wilms tumor cells was grafted in left kidney of 32 mice. Once tumors had >5mm diameter, mice received : placebo, N=14; Bevacizumab for 21days, N=11; and Bevacizumab for 10days followed by placebo for 11days, N = 7. On days -1, +1, +9, +14 and +21 with respect to treatment start, fUSI was performed (CPS mode, SonoVue). Linear time intensity curves were obtained from regions in kidney cortex and matched-depth of tumor for first bolus passage and 50s following acoustic destruction of contrast. Excised tumor weight decreased with increased treatment duration: 3.7+/-1.8 g (placebo), 2.3+/-1.9 g (Bevacizumab-10days, placebo-11days), 1.4+/-0.7 g (Bevacizumab-21 days) [p